Geneva, Switzerland
FluoSphera, founded in 2021 and headquartered in Switzerland, stands out as a pioneer in the biotechnology and life sciences industry. With its slogan, "The only company with a suite of systemic and high-throughput in vitro drug discovery solutions," the firm emphasizes its unique value proposition.
The company’s innovative approach leverages a proprietary chip-free platform that uses flexible 3D cell systems, allowing for an exceptional simulation of human biological responses. This enables accelerated and precise assessments of systemic drug interactions.
FluoSphera's solutions encompass multiplexing for target selectivity, systemic efficacy and toxicity measurement, biomarker identification, and translational species optimization, ensuring comprehensive drug discovery support.
The company recently secured a €1.23M Early VC investment from leading investors such as indiebio and Soulmates Ventures on 01 January 2026, underscoring confidence in its cutting-edge solutions and market potential.
